Table 2.
Immune-related adverse events in patients who received vaccination within 72 h of ICI treatment
| Vaccination within 72 hours (n = 19) | |||
|---|---|---|---|
| irAE (n = 5) | No irAE (n = 14) | p value | |
| Age | 0.74 | ||
| Median (range) | 65 (42–81) | 63 (46–83) | |
| Sex: | 0.5 | ||
| Female | 1 (20%) | 5 (36%) | |
| Male | 4 (80%) | 9 (64%) | |
| Anticancer therapy: | 0.39 | ||
| PD-1 antibody | 2 (40%) | 9 (64%) | |
| PD-L1 antibody | 0 (0%) | 1 (7%) | |
| CTLA4 + PD-1 antibody | 3 (60%) | 4 (29%) | |
| Type of vaccine received by vaccinated patients: | 0.36 | ||
| BioNTech | 5 (100) | 11 (79%) | |
| Moderna | 0 (0%) | 0 (0%) | |
| AstraZeneca | 0 (0%) | 2 (14%) | |
| AstraZeneca + BioNTech | 0 (0%) | 1 (7%) | |
| Johnson & Johnson | 0 (0%) | 0 (0%) | |
| Sequence of treatment | 0.7 | ||
| Vaccination -ICI | 2 (40%) | 7 (50%) | |
| ICI -vaccination | 3 (60%) | 7 (50%) | |
| irAEs before vaccination | 0.06 | ||
| Yes | 0 (0%) | 5 (36%) | |
| No | 5 (100%) | 0 (0%) | |
ICI, Immune checkpoint inhibitors; irAE, Immune-related adverse event.